Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gross Profit (2016 - 2025)

Amphastar Pharmaceuticals has reported Gross Profit over the past 13 years, most recently at $85.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $85.7 million for Q4 2025, down 1.13% from a year ago — trailing twelve months through Dec 2025 was $356.1 million (down 4.76% YoY), and the annual figure for FY2025 was $356.1 million, down 4.76%.
  • Gross Profit for Q4 2025 was $85.7 million at Amphastar Pharmaceuticals, down from $98.6 million in the prior quarter.
  • Over the last five years, Gross Profit for AMPH hit a ceiling of $108.4 million in Q3 2023 and a floor of $44.9 million in Q1 2021.
  • Median Gross Profit over the past 5 years was $79.5 million (2023), compared with a mean of $76.5 million.
  • Biggest five-year swings in Gross Profit: surged 85.27% in 2023 and later dropped 9.87% in 2024.
  • Amphastar Pharmaceuticals' Gross Profit stood at $56.2 million in 2021, then increased by 26.56% to $71.2 million in 2022, then skyrocketed by 35.09% to $96.1 million in 2023, then fell by 9.87% to $86.6 million in 2024, then dropped by 1.13% to $85.7 million in 2025.
  • The last three reported values for Gross Profit were $85.7 million (Q4 2025), $98.6 million (Q3 2025), and $86.5 million (Q2 2025) per Business Quant data.